Literature DB >> 21595627

XDR-TB, what is it; how is it treated; and why is therapeutic failure so high?

Stephen H Gillespie1, Kasha Singh.   

Abstract

Drug resistance is a major hurdle in the global battle against tuberculosis (TB). In tackling this problem it is important to understand both how resistance emerges as well as the ways in which multi-drug and extensively drug-resistant TB (M/XDR-TB) may be successfully treated. The biggest problem with treatment is the lack of effective drugs. Exciting developments have been made in this area over recent years with useful drugs being found from older agents as well as new discoveries. Patent applications are being made for novel agents and are also possible as new use for older agents such as thioridazine. A flourishing drug pipeline is critical if we are to make progress in the management of M/XDR-TB.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21595627     DOI: 10.2174/157489111796064641

Source DB:  PubMed          Journal:  Recent Pat Antiinfect Drug Discov        ISSN: 1574-891X


  4 in total

1.  Effect of targeted nursing intervention plus psychological counseling on quality of life, negative emotions, and complications in patients with extensively drug-resistant tuberculosis.

Authors:  Yanhua Lu; Hongqian Wang; Jianfeng Zhu; Na Wang; Dan Cui; Lingdi Li
Journal:  Am J Transl Res       Date:  2021-12-15       Impact factor: 4.060

2.  Structure of apo- and monometalated forms of NDM-1--a highly potent carbapenem-hydrolyzing metallo-β-lactamase.

Authors:  Youngchang Kim; Christine Tesar; Joseph Mire; Robert Jedrzejczak; Andrew Binkowski; Gyorgy Babnigg; James Sacchettini; Andrzej Joachimiak
Journal:  PLoS One       Date:  2011-09-08       Impact factor: 3.240

3.  Combating Ebola with Repurposed Therapeutics Using the CANDO Platform.

Authors:  Gaurav Chopra; Sashank Kaushik; Peter L Elkin; Ram Samudrala
Journal:  Molecules       Date:  2016-11-25       Impact factor: 4.411

4.  Computational chemoproteomics to understand the role of selected psychoactives in treating mental health indications.

Authors:  Jonathan Fine; Rachel Lackner; Ram Samudrala; Gaurav Chopra
Journal:  Sci Rep       Date:  2019-09-11       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.